U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C17H22N2O.C4H6O4
Molecular Weight 388.4574
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DOXYLAMINE SUCCINATE

SMILES

OC(=O)CCC(O)=O.CN(C)CCOC(C)(C1=CC=CC=C1)C2=CC=CC=N2

InChI

InChIKey=KBAUFVUYFNWQFM-UHFFFAOYSA-N
InChI=1S/C17H22N2O.C4H6O4/c1-17(20-14-13-19(2)3,15-9-5-4-6-10-15)16-11-7-8-12-18-16;5-3(6)1-2-4(7)8/h4-12H,13-14H2,1-3H3;1-2H2,(H,5,6)(H,7,8)

HIDE SMILES / InChI

Molecular Formula C4H6O4
Molecular Weight 118.088
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C17H22N2O
Molecular Weight 270.3694
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/cdi/doxylamine.html

Doxylamine is an antihistamine commonly used as a sleep aid. This drug is also used to relieve symptoms of hay fever (allergic rhinitis), hives (rash or itching), and other allergic reactions. Doxylamine is a member of the ethanolamine class of antihistamines and has anti-allergy power far superior to virtually every other antihistamine on the market, with the exception of diphenhydramine (Benadryl). It is also the most powerful over-the-counter sedative available in the United States, and more sedating than many prescription hypnotics. In a study, it was found to be superior to even the barbiturate, phenobarbital for use as a sedative. Doxylamine is also a potent anticholinergic. Like other antihistamines, doxylamine acts by competitively inhibiting histamine at H1 receptors. It also has substantial sedative and anticholinergic effects. Used alone as a short-term sleep aid, in combination with other drugs as a night-time cold and allergy relief drug. Also used in combination with Vitamin B6 (pyridoxine) to prevent morning sickness in pregnant women.

CNS Activity

Curator's Comment: Penetrating into the central nervous system, the drug has a marked sedative effect, promoting sleep.

Originator

Curator's Comment: Bendectin (DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE) was introduced in 1957 by Merrell Dow Pharmaceuticals

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
42.0 nM [Ki]
200.0 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unisom

Approved Use

Allergic rhinitis or other respiratory allergies (oral liquid only): Temporary relief of rhinorrhea, sneezing, itchy nose or throat, and itchy, watery eyes due to hay fever or other respiratory allergies Insomnia (tablets only): Reduce difficulty falling asleep

Launch Date

2.56089604E11
Primary
Unisom

Approved Use

Allergic rhinitis or other respiratory allergies (oral liquid only): Temporary relief of rhinorrhea, sneezing, itchy nose or throat, and itchy, watery eyes due to hay fever or other respiratory allergies Insomnia (tablets only): Reduce difficulty falling asleep

Launch Date

2.56089604E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
18.9 ng/mL
6.3 mg single, nasal
dose: 6.3 mg
route of administration: Nasal
experiment type: SINGLE
co-administered:
DOXYLAMINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
27.1 ng/mL
12.7 mg single, nasal
dose: 12.7 mg
route of administration: Nasal
experiment type: SINGLE
co-administered:
DOXYLAMINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
142 ng/mL
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DOXYLAMINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
12.9 ng/mL
3.2 mg single, nasal
dose: 3.2 mg
route of administration: Nasal
experiment type: SINGLE
co-administered:
DOXYLAMINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
124.91 ng/mL
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DOXYLAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
61.94 ng/mL
12.5 mg single, oral
dose: 12.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DOXYLAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
99 ng/mL
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DOXYLAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
83.3 ng/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered: PYRIDOXINE HYDROCHLORIDE
DOXYLAMINE unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
168.6 ng/mL
40 mg 1 times / day multiple, oral
dose: 40 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered: PYRIDOXINE HYDROCHLORIDE
DOXYLAMINE unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
117.7 ng × h/mL
6.3 mg single, nasal
dose: 6.3 mg
route of administration: Nasal
experiment type: SINGLE
co-administered:
DOXYLAMINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
161.8 ng × h/mL
12.7 mg single, nasal
dose: 12.7 mg
route of administration: Nasal
experiment type: SINGLE
co-administered:
DOXYLAMINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
751.8 ng × h/mL
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DOXYLAMINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
81.1 ng × h/mL
3.2 mg single, nasal
dose: 3.2 mg
route of administration: Nasal
experiment type: SINGLE
co-administered:
DOXYLAMINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1697.58 ng × h/mL
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DOXYLAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
859.74 ng × h/mL
12.5 mg single, oral
dose: 12.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DOXYLAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1280.9 ng × h/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered: PYRIDOXINE HYDROCHLORIDE
DOXYLAMINE unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
3721.5 ng × h/mL
40 mg 1 times / day multiple, oral
dose: 40 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered: PYRIDOXINE HYDROCHLORIDE
DOXYLAMINE unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
11.8 h
6.3 mg single, nasal
dose: 6.3 mg
route of administration: Nasal
experiment type: SINGLE
co-administered:
DOXYLAMINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
10.1 h
12.7 mg single, nasal
dose: 12.7 mg
route of administration: Nasal
experiment type: SINGLE
co-administered:
DOXYLAMINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
10.4 h
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DOXYLAMINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
10.2 h
3.2 mg single, nasal
dose: 3.2 mg
route of administration: Nasal
experiment type: SINGLE
co-administered:
DOXYLAMINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
12.45 h
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DOXYLAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
12.23 h
12.5 mg single, oral
dose: 12.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DOXYLAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
10.1 h
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DOXYLAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
10.1 h
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered: PYRIDOXINE HYDROCHLORIDE
DOXYLAMINE unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
11.9 h
40 mg 1 times / day multiple, oral
dose: 40 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered: PYRIDOXINE HYDROCHLORIDE
DOXYLAMINE unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
150 mg single, oral
Overdose
Dose: 150 mg
Route: oral
Route: single
Dose: 150 mg
Sources: Page: p.179
unknown, 2
n = 1
Health Status: unknown
Age Group: 2
Sex: M
Population Size: 1
Sources: Page: p.179
Other AEs: Agitation, Dilated pupils...
Other AEs:
Agitation
Dilated pupils
Sources: Page: p.179
25 mg single, oral
Studied dose
Dose: 25 mg
Route: oral
Route: single
Dose: 25 mg
Sources: Page: p.133
healthy, 28 - 58
n = 12
Health Status: healthy
Age Group: 28 - 58
Sex: M+F
Population Size: 12
Sources: Page: p.133
Other AEs: Somnolence...
Other AEs:
Somnolence (50%)
Sources: Page: p.133
12.7 mg single, intranasal
Highest studied dose
Dose: 12.7 mg
Route: intranasal
Route: single
Dose: 12.7 mg
Sources: Page: p.133
unhealthy, 35.9 (8.00)
n = 24
Health Status: unhealthy
Condition: Chronic intermittent sleep impairment
Age Group: 35.9 (8.00)
Sex: M+F
Population Size: 24
Sources: Page: p.133
13 mg/kg single, oral
Overdose
Dose: 13 mg/kg
Route: oral
Route: single
Dose: 13 mg/kg
Sources: Page: p.1
unknown
Health Status: unknown
Sources: Page: p.1
Other AEs: Rhabdomyolysis...
Other AEs:
Rhabdomyolysis
Sources: Page: p.1
20 mg 2 times / day multiple, oral
Recommended
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Co-administed with::
pyridoxine hydrochloride(20 mg oral; 1-2/day)
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Nausea and vomiting of pregnancy
Sources: Page: p.1
Other AEs: Somnolence...
20 mg 2 times / day multiple, oral
Recommended
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Co-administed with::
pyridoxine hydrochloride(20 mg oral; 1-2/day)
CNS depressants
Sources: Page: p.3
unhealthy
Health Status: unhealthy
Condition: Nausea and vomiting of pregnancy
Sources: Page: p.3
Other AEs: Drowsiness...
Other AEs:
Drowsiness (grade 3)
Sources: Page: p.3
20 mg single, oral
Recommended
Dose: 20 mg
Route: oral
Route: single
Dose: 20 mg
Co-administed with::
pyridoxine hydrochloride(20 mg oral single dose)
Sources: Page: p.48
healthy
n = 48
Health Status: healthy
Sex: F
Population Size: 48
Sources: Page: p.48
Disc. AE: Vomiting...
AEs leading to
discontinuation/dose reduction:
Vomiting
Sources: Page: p.48
20 mg 2 times / day steady, oral
Recommended
Dose: 20 mg, 2 times / day
Route: oral
Route: steady
Dose: 20 mg, 2 times / day
Co-administed with::
pyridoxine hydrochloride(20 mg oral single dose)
Sources: Page: p.63
healthy
n = 37
Health Status: healthy
Sex: F
Population Size: 37
Sources: Page: p.63
Disc. AE: Vomiting, Decreased hemoglobin...
AEs leading to
discontinuation/dose reduction:
Vomiting
Decreased hemoglobin
Visual impairment
Sources: Page: p.63
AEs

AEs

AESignificanceDosePopulation
Agitation
150 mg single, oral
Overdose
Dose: 150 mg
Route: oral
Route: single
Dose: 150 mg
Sources: Page: p.179
unknown, 2
n = 1
Health Status: unknown
Age Group: 2
Sex: M
Population Size: 1
Sources: Page: p.179
Dilated pupils
150 mg single, oral
Overdose
Dose: 150 mg
Route: oral
Route: single
Dose: 150 mg
Sources: Page: p.179
unknown, 2
n = 1
Health Status: unknown
Age Group: 2
Sex: M
Population Size: 1
Sources: Page: p.179
Somnolence 50%
25 mg single, oral
Studied dose
Dose: 25 mg
Route: oral
Route: single
Dose: 25 mg
Sources: Page: p.133
healthy, 28 - 58
n = 12
Health Status: healthy
Age Group: 28 - 58
Sex: M+F
Population Size: 12
Sources: Page: p.133
Rhabdomyolysis
13 mg/kg single, oral
Overdose
Dose: 13 mg/kg
Route: oral
Route: single
Dose: 13 mg/kg
Sources: Page: p.1
unknown
Health Status: unknown
Sources: Page: p.1
Somnolence
20 mg 2 times / day multiple, oral
Recommended
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Co-administed with::
pyridoxine hydrochloride(20 mg oral; 1-2/day)
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Nausea and vomiting of pregnancy
Sources: Page: p.1
Drowsiness grade 3
20 mg 2 times / day multiple, oral
Recommended
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Co-administed with::
pyridoxine hydrochloride(20 mg oral; 1-2/day)
CNS depressants
Sources: Page: p.3
unhealthy
Health Status: unhealthy
Condition: Nausea and vomiting of pregnancy
Sources: Page: p.3
Vomiting Disc. AE
20 mg single, oral
Recommended
Dose: 20 mg
Route: oral
Route: single
Dose: 20 mg
Co-administed with::
pyridoxine hydrochloride(20 mg oral single dose)
Sources: Page: p.48
healthy
n = 48
Health Status: healthy
Sex: F
Population Size: 48
Sources: Page: p.48
Decreased hemoglobin Disc. AE
20 mg 2 times / day steady, oral
Recommended
Dose: 20 mg, 2 times / day
Route: oral
Route: steady
Dose: 20 mg, 2 times / day
Co-administed with::
pyridoxine hydrochloride(20 mg oral single dose)
Sources: Page: p.63
healthy
n = 37
Health Status: healthy
Sex: F
Population Size: 37
Sources: Page: p.63
Visual impairment Disc. AE
20 mg 2 times / day steady, oral
Recommended
Dose: 20 mg, 2 times / day
Route: oral
Route: steady
Dose: 20 mg, 2 times / day
Co-administed with::
pyridoxine hydrochloride(20 mg oral single dose)
Sources: Page: p.63
healthy
n = 37
Health Status: healthy
Sex: F
Population Size: 37
Sources: Page: p.63
Vomiting Disc. AE
20 mg 2 times / day steady, oral
Recommended
Dose: 20 mg, 2 times / day
Route: oral
Route: steady
Dose: 20 mg, 2 times / day
Co-administed with::
pyridoxine hydrochloride(20 mg oral single dose)
Sources: Page: p.63
healthy
n = 37
Health Status: healthy
Sex: F
Population Size: 37
Sources: Page: p.63
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer





Drug as perpetrator​
PubMed

PubMed

TitleDatePubMed
The expert witness. Neither Frye nor Daubert solved the problem: what can be done?
2001 Jan-Mar
Suicide through doxylamine poisoning.
2001 Jun 1
A comparative study of an in situ adapted diffusion cell and an in vitro Franz diffusion cell method for transdermal absorption of doxylamine.
2001 May
Quantitation of antihistamines in pharmaceutical preparations by liquid chromatography with a micellar mobile phase of sodium dodecyl sulfate and pentanol.
2001 Nov-Dec
Bendectin.
2001 Nov-Dec
Immunoassay screening of lysergic acid diethylamide (LSD) and its confirmation by HPLC and fluorescence detection following LSD ImmunElute extraction.
2002 Apr
Medical, social, and legal implications of treating nausea and vomiting of pregnancy.
2002 May
[A new approach to the treatment of sleep disorders in patients with cerebrovascular diseases].
2003
Science v. law. A decade-old rule on scientific evidence comes under fire.
2003 Dec
Pharmacologic interventions in the treatment of temporomandibular disorders, atypical facial pain, and burning mouth syndrome. A qualitative systematic review.
2003 Fall
Nausea and vomiting of pregnancy.
2003 Jul 1
Antihistamine-induced rhabdomyolysis.
2003 Oct
Diclectin therapy for nausea and vomiting of pregnancy: effects of optimal dosing.
2003 Oct
[Hyperemesis gravidarum--etiology and treatment].
2003 Sep-Oct
Pre-emptive therapy for severe nausea and vomiting of pregnancy and hyperemesis gravidarum.
2004 Aug
Is lack of morning sickness teratogenic? A prospective controlled study.
2004 Aug
Differential protonation and dynamic structure of doxylamine succinate in solution using 1H and 13C NMR.
2004 Jul
Determinants of women's decision making on whether to treat nausea and vomiting of pregnancy pharmacologically.
2004 Jul-Aug
An assessment of quality of sleep and the use of drugs with sedating properties in hospitalized adult patients.
2004 Mar 24
Steady-state brain concentrations of antihistamines in rats: interplay of membrane permeability, P-glycoprotein efflux and plasma protein binding.
2004 Oct
Prophylactic Diclectin reduces the incidence of postoperative vomiting.
2005 Jan
[Detection of reladorm and donormil in forensic-medical examination of cadavers].
2005 Mar-Apr
[Efficacy of donormil in the treatment of insomnia in patients with vascular encephalopathy].
2006
Therapy insight: drugs for gastrointestinal disorders in pregnant women.
2006 May
Optimization by factorial design of a capillary zone electrophoresis method for the simultaneous separation of antihistamines.
2006 May 1
OTC product: Zicam Cold and Flu Medicated Spoons.
2006 Nov-Dec
[Juvenile pityriasis rubra pilaris].
2006 Oct
[Unilateral laterothoracic exanthema].
2006 Oct
Vanished behind the counter. Starting this week, you'll need help buying your claritin and nyquil.
2006 Oct 2
Efficacy of a single evening dose of syrup containing paracetamol, dextromethorphan hydrobromide, doxylamine succinate and ephedrine sulfate in subjects with multiple common cold symptoms.
2007 Apr
Comparison of lactated Ringer's solution and 0.9% saline in the treatment of rhabdomyolysis induced by doxylamine intoxication.
2007 Apr
Inactivation of anthracyclines by serum heme proteins.
2007 Jun
Separation of cold medicine ingredients using a precise MEKC method at elevated pH.
2007 Jun
Possible role of pseudoephedrine and other over-the-counter cold medications in the deaths of very young children.
2007 Mar
Differentially expressed genes in embryonic cardiac tissues of mice lacking Folr1 gene activity.
2007 Nov 20
Managing nausea and vomiting of pregnancy: a survey of obstetrician-gynecologists.
2007 Oct
[Is good care (only) guaranteed by a specialist?].
2008 Apr 15
"DXemon juice:" analytical evaluation of an extraction process for the purification and freebasing of dextromethorphan from cold preparations.
2008 Dec
Sleep complaints: Whenever possible, avoid the use of sleeping pills.
2008 Oct
Simultaneous determination of a ternary mixture of doxylamine succinate, pyridoxine hydrochloride, and folic acid by the ratio spectra-zero-crossing, double divisor-ratio spectra derivative, and column high-performance liquid chromatographic methods.
2008 Sep-Oct
Pharmacokinetic comparison of a delayed-release combination of doxylamine succinate and pyridoxine hydrocholoride (Diclectin) and oral solutions of these drugs in healthy women of childbearing age.
2009 Fall
Long-term neurodevelopment of children exposed to maternal nausea and vomiting of pregnancy and diclectin.
2009 Jul
Comparison of chiral separation of basic drugs in capillary electrophoresis and liquid chromatography using neutral and negatively charged cyclodextrins.
2009 Jul 10
Does advice from pharmacy staff vary according to the nonprescription medicine requested?
2009 Nov
Drugs associated with more suicidal ideations are also associated with more suicide attempts.
2009 Oct 2
Learning curves for pediatric laparoscopy: how many operations are enough? The Amsterdam experience with laparoscopic pyloromyotomy.
2010 Aug
Optimal management of nausea and vomiting of pregnancy.
2010 Aug 4
Authenticity of claims made in drug promotional literature.
2010 Feb
A tendency for re-offending in drug-facilitated crime.
2010 Mar 20
Clinical practice. Nausea and vomiting in pregnancy.
2010 Oct 14
Patents

Sample Use Guides

In Vivo Use Guide
Usual Adult Dose for Allergic Rhinitis Doxylamine 5 mg oral tablet, chewable: 10 mg orally every 4 to 6 hours not to exceed 6 doses daily. Usual Adult Dose for Allergic Conjunctivitis Doxylamine 5 mg oral tablet, chewable: 10 mg orally every 4 to 6 hours not to exceed 6 doses daily. Usual Adult Dose for Insomnia 12 years of age and older: 25 mg orally 30 minutes before bed
Route of Administration: Oral
In Vitro Use Guide
Doxylamine at 50 ug/ml inhibited both differentiation and proliferation in rat embryo limb bud cell cultures
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:01:13 UTC 2023
Edited
by admin
on Fri Dec 15 15:01:13 UTC 2023
Record UNII
V9BI9B5YI2
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DOXYLAMINE SUCCINATE
GREEN BOOK   MART.   MI   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD  
Common Name English
DORMIDINA
Brand Name English
MERAPRINA
Brand Name English
UNISOM
Brand Name English
DOXYLAMINE SUCCINATE [USP MONOGRAPH]
Common Name English
DICLECTIN COMPONENT DOXYLAMINE SUCCINATE
Brand Name English
DONORMYL
Brand Name English
DOXYLAMINE SUCCINATE COMPONENT OF DICLEGIS
Brand Name English
ALSODORM
Brand Name English
DOXYLAMINE SUCCINATE COMPONENT OF BONJESTA
Brand Name English
DOXYLAMINE SUCCINATE [USP-RS]
Common Name English
DICLEGIS COMPONENT DOXYLAMINE SUCCINATE
Brand Name English
DOXYLAMINE SUCCINATE [ORANGE BOOK]
Common Name English
GITTALUN
Brand Name English
DOXYLAMINE SUCCINATE [GREEN BOOK]
Common Name English
DECAPRYN
Brand Name English
DOXYLAMINE HYDROGEN SUCCINATE [EP MONOGRAPH]
Common Name English
DOXYLAMINE SUCCINATE COMPONENT OF BENDECTIN
Common Name English
DOXY-SLEEP-AID
Brand Name English
N,N-DIMETHYL-2-((1RS)-1-PHENYL-1-(PYRIDIN-2-YL)ETHOXY(ETHANAMINE HYDROGEN BUTANEDIOATE
Common Name English
DOXYLAMINE SUCCINATE [MART.]
Common Name English
Doxylamine succinate [WHO-DD]
Common Name English
DOXYLAMINE HYDROGEN SUCCINATE
EP  
Common Name English
NSC-74772
Code English
DOXYLAMINE SUCCINATE [VANDF]
Common Name English
DOXYLAMINE SUCCINATE [IARC]
Common Name English
HOGGAR N
Brand Name English
BONJESTA COMPONENT DOXYLAMINE SUCCINATE
Brand Name English
DECAMIUM
Systematic Name English
DOXYLAMINE SUCCINATE [MI]
Common Name English
DOXYLAMINE HYDROGEN SUCCINATE [EP IMPURITY]
Common Name English
DONORMIL
Brand Name English
2-[α[2-(Dimethylamino)ethoxy]-α-methylbenzyl]pyridine succinate (1:1)
Systematic Name English
BENDECTIN COMPONENT DOXYLAMINE SUCCINATE
Brand Name English
ETHANAMINE, N,N-DIMETHYL-2-(1-PHENYL-1-(2-PYRIDINYL)ETHOXY)-, BUTANEDIOATE (1:1)
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C29578
Created by admin on Fri Dec 15 15:01:13 UTC 2023 , Edited by admin on Fri Dec 15 15:01:13 UTC 2023
CFR 21 CFR 341.12
Created by admin on Fri Dec 15 15:01:13 UTC 2023 , Edited by admin on Fri Dec 15 15:01:13 UTC 2023
CFR 21 CFR 522.784
Created by admin on Fri Dec 15 15:01:13 UTC 2023 , Edited by admin on Fri Dec 15 15:01:13 UTC 2023
Code System Code Type Description
NSC
74772
Created by admin on Fri Dec 15 15:01:13 UTC 2023 , Edited by admin on Fri Dec 15 15:01:13 UTC 2023
PRIMARY
RXCUI
23665
Created by admin on Fri Dec 15 15:01:13 UTC 2023 , Edited by admin on Fri Dec 15 15:01:13 UTC 2023
PRIMARY RxNorm
SMS_ID
100000087529
Created by admin on Fri Dec 15 15:01:13 UTC 2023 , Edited by admin on Fri Dec 15 15:01:13 UTC 2023
PRIMARY
PUBCHEM
11224
Created by admin on Fri Dec 15 15:01:13 UTC 2023 , Edited by admin on Fri Dec 15 15:01:13 UTC 2023
PRIMARY
CAS
562-10-7
Created by admin on Fri Dec 15 15:01:13 UTC 2023 , Edited by admin on Fri Dec 15 15:01:13 UTC 2023
PRIMARY
NCI_THESAURUS
C47501
Created by admin on Fri Dec 15 15:01:13 UTC 2023 , Edited by admin on Fri Dec 15 15:01:13 UTC 2023
PRIMARY
ECHA (EC/EINECS)
209-228-7
Created by admin on Fri Dec 15 15:01:13 UTC 2023 , Edited by admin on Fri Dec 15 15:01:13 UTC 2023
PRIMARY
MERCK INDEX
m4759
Created by admin on Fri Dec 15 15:01:13 UTC 2023 , Edited by admin on Fri Dec 15 15:01:13 UTC 2023
PRIMARY Merck Index
RS_ITEM_NUM
1227006
Created by admin on Fri Dec 15 15:01:13 UTC 2023 , Edited by admin on Fri Dec 15 15:01:13 UTC 2023
PRIMARY
DAILYMED
V9BI9B5YI2
Created by admin on Fri Dec 15 15:01:13 UTC 2023 , Edited by admin on Fri Dec 15 15:01:13 UTC 2023
PRIMARY
EVMPD
SUB01834MIG
Created by admin on Fri Dec 15 15:01:13 UTC 2023 , Edited by admin on Fri Dec 15 15:01:13 UTC 2023
PRIMARY
DRUG BANK
DBSALT001402
Created by admin on Fri Dec 15 15:01:13 UTC 2023 , Edited by admin on Fri Dec 15 15:01:13 UTC 2023
PRIMARY
MESH
C035385
Created by admin on Fri Dec 15 15:01:13 UTC 2023 , Edited by admin on Fri Dec 15 15:01:13 UTC 2023
PRIMARY
FDA UNII
V9BI9B5YI2
Created by admin on Fri Dec 15 15:01:13 UTC 2023 , Edited by admin on Fri Dec 15 15:01:13 UTC 2023
PRIMARY
ChEMBL
CHEMBL1004
Created by admin on Fri Dec 15 15:01:13 UTC 2023 , Edited by admin on Fri Dec 15 15:01:13 UTC 2023
PRIMARY
EPA CompTox
DTXSID7020552
Created by admin on Fri Dec 15 15:01:13 UTC 2023 , Edited by admin on Fri Dec 15 15:01:13 UTC 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
ACTIVE MOIETY